4 news items
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
TAK
17 Jun 24
in convulsive seizure frequency compared to placebo (p-value = 0.001).
Takeda will engage with regulatory authorities to discuss the totality
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
results on the primary endpoints, we are encouraged by positive outcomes seen in the totality of the data and are looking forward to engaging health
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
.This partnership and commercial engagement builds upon Pentavere winning the Takeda Canada Innovation Challenge
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
TAK
22 Apr 24
. In response to this challenge, the three companies have been engaged in discussions to establish a joint venture company that will seamlessly cover the entire
- Prev
- 1
- Next